Skip to content
ClinCalc Pro
Menu
Antispasmodic — Ureteric Spasm

Hyoscine Butylbromide

Brand names: Buscopan

Hyoscine butylbromide (an antimuscarinic and smooth-muscle relaxant) is used for relief of abdominal and genitourinary smooth-muscle spasm, including ureteric/renal colic and bladder spasm, available as oral tablets and as an injection.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

As a quaternary-ammonium antimuscarinic it blocks acetylcholine at muscarinic receptors on visceral smooth muscle, relaxing spasm in the gut and urinary tract.

Prescribing in practice

  • Given parenterally it can cause tachycardia, hypotension and, rarely, serious anaphylaxis, so injectable use needs caution and monitoring, especially in patients with cardiac disease.
  • Avoid in conditions worsened by antimuscarinic action, such as untreated angle-closure glaucoma, myasthenia gravis, paralytic ileus and significant bladder outflow obstruction.
  • Poor oral bioavailability means the injectable route is used when a rapid antispasmodic effect is required.

Monitoring

No routine laboratory monitoring is needed; observe heart rate and blood pressure when given by injection and review symptom relief.

Counselling the patient

  • It is used for short-term relief of cramping spasm pain.
  • Report eye pain or sudden visual disturbance, which could indicate raised intraocular pressure.

Evidence & guidelines

Hyoscine butylbromide is an established antispasmodic for visceral smooth-muscle colic, with long-standing clinical use supported by the SPC.

Reference: RCEM Clinical Standards; Cochrane Review (antispasmodics for renal colic, 2014); EAU Urolithiasis Guidelines 2024; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.